Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
CNY 31.24
(-0.13%)
CNY 31.24
(-0.13%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 160.98 Million CNY | 14.28% |
| 2022 | 140.86 Million CNY | 35.86% |
| 2021 | 103.68 Million CNY | 23.39% |
| 2020 | 84.02 Million CNY | 39.09% |
| 2019 | 60.41 Million CNY | 16.86% |
| 2018 | 51.69 Million CNY | -5.89% |
| 2017 | 54.92 Million CNY | 29.71% |
| 2016 | 42.34 Million CNY | 31.25% |
| 2015 | 32.26 Million CNY | 13.4% |
| 2014 | 28.45 Million CNY | -0.79% |
| 2013 | 28.67 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 184.32 Million CNY | 0.47% |
| 2024 Q1 | 174.53 Million CNY | 8.42% |
| 2024 Q2 | 183.46 Million CNY | 5.12% |
| 2023 Q2 | 162.8 Million CNY | 4.4% |
| 2023 FY | 160.98 Million CNY | 14.28% |
| 2023 Q3 | 161.81 Million CNY | -0.61% |
| 2023 Q1 | 155.94 Million CNY | 10.7% |
| 2023 Q4 | 160.98 Million CNY | -0.51% |
| 2022 Q2 | 126.07 Million CNY | 4.07% |
| 2022 Q1 | 121.14 Million CNY | 16.84% |
| 2022 FY | 140.86 Million CNY | 35.86% |
| 2022 Q4 | 140.86 Million CNY | 13.8% |
| 2022 Q3 | 123.78 Million CNY | -1.82% |
| 2021 FY | 103.68 Million CNY | 23.39% |
| 2021 Q4 | 103.68 Million CNY | 15.39% |
| 2021 Q1 | 87.96 Million CNY | 4.68% |
| 2021 Q2 | 89.79 Million CNY | 2.08% |
| 2021 Q3 | 89.85 Million CNY | 0.06% |
| 2020 Q2 | 73.94 Million CNY | 0.0% |
| 2020 FY | 84.02 Million CNY | 39.09% |
| 2020 Q3 | 81.51 Million CNY | 10.23% |
| 2020 Q4 | 84.02 Million CNY | 3.09% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 FY | 60.41 Million CNY | 16.86% |
| 2019 Q4 | 60.41 Million CNY | 0.0% |
| 2018 FY | 51.69 Million CNY | -5.89% |
| 2017 FY | 54.92 Million CNY | 29.71% |
| 2016 Q2 | 35.97 Million CNY | 0.0% |
| 2016 Q1 | 35.97 Million CNY | 11.51% |
| 2016 FY | 42.34 Million CNY | 31.25% |
| 2015 Q4 | 32.26 Million CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 FY | 32.26 Million CNY | 13.4% |
| 2014 FY | 28.45 Million CNY | -0.79% |
| 2013 FY | 28.67 Million CNY | 0.0% |